Recombinant protein · Protein replacement: beta-lactam antibiotics (hydrolyzed in the intestine) · developed by Theriva Biologics
Ribaxamase (SYN-004) is an orally administered recombinant beta-lactamase enzyme. It hydrolyzes the beta-lactam ring of intravenously given beta-lactam antibiotics that reach the intestine, aiming to protect the gut microbiome. It is studied in the context of Clostridium difficile infection and antibiotic-associated diarrhea.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT02563106 | Phase 2 | Clostridium Difficile | Completed | TOVX |
| NCT02419001 | Phase 1/2 | Healthy Volunteers | Completed | TOVX |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Clostridium DifficileClostridium InfectionsHealthy Volunteers
Updated Nov 1, 2026. Something wrong or missing? Report it on the TOVX page.
See TOVX's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
TOVX catalysts and pipeline →